Enfuvirtide + Tenofovir-Emtricitabine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukoencephalopathy, Progressive Multifocal
Conditions
Leukoencephalopathy, Progressive Multifocal, HIV Infections
Trial Timeline
Apr 1, 2005 → Dec 1, 2007
NCT ID
NCT00120367About Enfuvirtide + Tenofovir-Emtricitabine
Enfuvirtide + Tenofovir-Emtricitabine is a phase 2 stage product being developed by Roche for Leukoencephalopathy, Progressive Multifocal. The current trial status is completed. This product is registered under clinical trial identifier NCT00120367. Target conditions include Leukoencephalopathy, Progressive Multifocal, HIV Infections.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00120367 | Phase 2 | Completed |
Competing Products
2 competing products in Leukoencephalopathy, Progressive Multifocal
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mefloquine | Biogen | Phase 1/2 | 38 |
| Tysabri | Biogen | Pre-clinical | 20 |